RPS6KA6 and nonpapillary renal cell carcinoma: We further verified the role of RSK4 in ccRCC angiogenesis by detecting the phosphorylation of MAPK using the rps6 antibody in ACHN cell lines expressing endogenous RSK4 after treatment with the RSK inhibitor BI-D1870 (Figure 5a).